Apellis Pharmaceuticals, Inc. (APLS) reported $166.8 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.2%. EPS of -$0.74 for the same period compares to -$0.54 a year ago.
The reported revenue represents a surprise of -13.33% over the Zacks Consensus Estimate of $192.44 million. With the consensus EPS estimate being -$0.36, the EPS surprise was -105.56%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Apellis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product revenue, net: $149.90 million versus $181.79 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a -8.1% change.
- Revenue- Licensing and other revenue: $16.90 million versus the 10-analyst average estimate of $13.31 million. The reported number represents a year-over-year change of +82.7%.
- Product Revenue- EMPAVELI: $19.73 million versus the seven-analyst average estimate of $23.67 million.
- Product Revenue- SYFOVRE: $130.17 million compared to the $156.94 million average estimate based on seven analysts.
View all Key Company Metrics for Apellis Pharmaceuticals here>>>
Shares of Apellis Pharmaceuticals have returned +2.3% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apellis Pharmaceuticals, Inc. (APLS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
